Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126818871 | 12681887 | 1 | I | 20141121 | 20160812 | 20160824 | 20160824 | EXP | FR-MYLANLABS-2016M1034474 | MYLAN | 0.00 | Y | 0.00000 | 20160824 | OT | FR | FR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126818871 | 12681887 | 1 | PS | Vancomycin Mylan | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 1500 MG, BID | 93000 | MG | Y | U | 65397 | 1500 | MG | BID | |||
126818871 | 12681887 | 2 | SS | MYLAN-CIPROFLOXACIN | CIPROFLOXACIN | 1 | Oral | 750 MG, BID | 46500 | MG | Y | U | 0 | 750 | MG | BID | |||
126818871 | 12681887 | 3 | SS | AMIKACIN MYLAN | AMIKACIN | 1 | Intravenous (not otherwise specified) | 2 G, QD | 8 | G | Y | U | 0 | 2 | G | QD | |||
126818871 | 12681887 | 4 | SS | DOMPERIDONE ARROW /00498201/ | DOMPERIDONE | 1 | Oral | 10 TO 30 MG DAILY | Y | U | 0 | QD | |||||||
126818871 | 12681887 | 5 | SS | LOVENOX | ENOXAPARIN SODIUM | 1 | Subcutaneous | 4000 IU, QD | Y | U | 0 | 4000 | IU | QD | |||||
126818871 | 12681887 | 6 | SS | INEXIUM /01479302/ | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 20 MG, QD | 80 | MG | Y | U | 0 | 20 | MG | QD | |||
126818871 | 12681887 | 7 | SS | ATARAX | HYDROXYZINEHYDROXYZINE HYDROCHLORIDE | 1 | Oral | 25 MG, QD | 25 | MG | Y | U | 0 | 25 | MG | QD | |||
126818871 | 12681887 | 8 | SS | OXYNORMORO | OXYCODONE | 1 | Oral | 5 MG, QD | 5 | MG | Y | U | 0 | 5 | MG | QD | |||
126818871 | 12681887 | 9 | SS | ACUPAN | NEFOPAM HYDROCHLORIDE | 1 | Oral | 20 MG, QID | 160 | MG | Y | U | 0 | 20 | MG | SOLUTION FOR INJECTION | QID | ||
126818871 | 12681887 | 10 | SS | DOLIPRANE | ACETAMINOPHEN | 1 | Oral | 1000 MG, QID | 28000 | MG | Y | U | 0 | 1000 | MG | QID |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126818871 | 12681887 | 1 | Postoperative wound infection |
126818871 | 12681887 | 2 | Postoperative wound infection |
126818871 | 12681887 | 3 | Postoperative wound infection |
126818871 | 12681887 | 4 | Prophylaxis of nausea and vomiting |
126818871 | 12681887 | 5 | Thrombosis prophylaxis |
126818871 | 12681887 | 6 | Product used for unknown indication |
126818871 | 12681887 | 7 | Product used for unknown indication |
126818871 | 12681887 | 8 | Pain prophylaxis |
126818871 | 12681887 | 9 | Pain prophylaxis |
126818871 | 12681887 | 10 | Pain prophylaxis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126818871 | 12681887 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126818871 | 12681887 | Drug reaction with eosinophilia and systemic symptoms | |
126818871 | 12681887 | Nausea | |
126818871 | 12681887 | Oedema peripheral | |
126818871 | 12681887 | Rash erythematous |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126818871 | 12681887 | 1 | 20141120 | 20141220 | 0 | |
126818871 | 12681887 | 2 | 20141120 | 20141220 | 0 | |
126818871 | 12681887 | 3 | 20141120 | 20141123 | 0 | |
126818871 | 12681887 | 4 | 20141122 | 20141128 | 0 | |
126818871 | 12681887 | 5 | 20141121 | 0 | ||
126818871 | 12681887 | 6 | 20141121 | 20141124 | 0 | |
126818871 | 12681887 | 7 | 20141119 | 20141119 | 0 | |
126818871 | 12681887 | 8 | 20141120 | 20141120 | 0 | |
126818871 | 12681887 | 9 | 20141121 | 20141122 | 0 | |
126818871 | 12681887 | 10 | 20141121 | 20141127 | 0 |